JPWO2023194530A5 - - Google Patents
Info
- Publication number
- JPWO2023194530A5 JPWO2023194530A5 JP2024559035A JP2024559035A JPWO2023194530A5 JP WO2023194530 A5 JPWO2023194530 A5 JP WO2023194530A5 JP 2024559035 A JP2024559035 A JP 2024559035A JP 2024559035 A JP2024559035 A JP 2024559035A JP WO2023194530 A5 JPWO2023194530 A5 JP WO2023194530A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- azd5305
- prostate cancer
- enzalutamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362613P | 2022-04-07 | 2022-04-07 | |
| US63/362,613 | 2022-04-07 | ||
| PCT/EP2023/059130 WO2023194530A1 (en) | 2022-04-07 | 2023-04-06 | Combination therapy for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025511402A JP2025511402A (ja) | 2025-04-15 |
| JP2025511402A5 JP2025511402A5 (https=) | 2026-04-10 |
| JPWO2023194530A5 true JPWO2023194530A5 (https=) | 2026-04-10 |
Family
ID=86226547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559035A Pending JP2025511402A (ja) | 2022-04-07 | 2023-04-06 | 癌を治療するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250213556A1 (https=) |
| EP (1) | EP4504182A1 (https=) |
| JP (1) | JP2025511402A (https=) |
| KR (1) | KR20240170957A (https=) |
| CN (1) | CN119212702A (https=) |
| AU (1) | AU2023250031A1 (https=) |
| CA (1) | CA3254949A1 (https=) |
| IL (1) | IL316017A (https=) |
| MX (1) | MX2024012392A (https=) |
| TW (1) | TW202404661A (https=) |
| WO (1) | WO2023194530A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202600137A (zh) * | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0705903B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Mutations in the 17q-linked breast and ovarian cancer susceptibility gene |
| DK0699754T3 (da) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
-
2023
- 2023-04-06 WO PCT/EP2023/059130 patent/WO2023194530A1/en not_active Ceased
- 2023-04-06 CN CN202380032432.8A patent/CN119212702A/zh active Pending
- 2023-04-06 EP EP23719651.4A patent/EP4504182A1/en active Pending
- 2023-04-06 US US18/853,504 patent/US20250213556A1/en active Pending
- 2023-04-06 JP JP2024559035A patent/JP2025511402A/ja active Pending
- 2023-04-06 KR KR1020247036944A patent/KR20240170957A/ko active Pending
- 2023-04-06 AU AU2023250031A patent/AU2023250031A1/en active Pending
- 2023-04-06 CA CA3254949A patent/CA3254949A1/en active Pending
- 2023-04-06 IL IL316017A patent/IL316017A/en unknown
- 2023-04-07 TW TW112113000A patent/TW202404661A/zh unknown
-
2024
- 2024-10-04 MX MX2024012392A patent/MX2024012392A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023041862A5 (https=) | ||
| JP2024015120A5 (https=) | ||
| JP2022180461A5 (https=) | ||
| JP5890780B2 (ja) | 中枢を介する悪心および嘔吐を治療するための組成物および方法 | |
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2020516646A5 (https=) | ||
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
| JP2016505050A5 (https=) | ||
| JP2004525143A5 (https=) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2022177119A5 (https=) | ||
| EP4494700A3 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| JPWO2023194530A5 (https=) | ||
| JPWO2023194528A5 (https=) | ||
| JPWO2023194525A5 (https=) | ||
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JPWO2022218956A5 (https=) | ||
| JPWO2020157577A5 (https=) | ||
| CN1537006A (zh) | 含有米尔塔扎平和对乙酰氨基酚或一种非甾类消炎药的用于治疗头痛的联合用药物 | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JP7653712B2 (ja) | 高リスク骨髄異形成症候群の治療薬 |